Literature DB >> 12760859

Clinical pharmacokinetics of cefamandole and ceftazidime administered by continuous intravenous infusion.

J Berkhout1, L G Visser, P J van den Broek, J A M van de Klundert, H Mattie.   

Abstract

In view of the results of animal studies as well as theoretical considerations, continuous administration of beta-lactam antibiotics should be superior to intermittent administration because of the close relationship between efficacy and the duration of time in which the concentration of unbound antibiotics in plasma remains above the MIC. The aim of the present study was to establish the pharmacokinetic parameters of cefamandole and ceftazidime for patients receiving these cephalosporins by continuous infusion. The interindividual differences in the concentrations in plasma at the steady state were mainly attributable to variations in renal function, as estimated by the rate of creatinine clearance. Using these results, we derived formulas for both cephalosporins that can be used to determine on an individual basis the total daily dose needed to obtain a therapeutic concentration in plasma. These formulas were tested with a group of subsequent patients and proved to be practical and fairly reliable. For some patients, a correction for a possible underestimation of the renal clearance at presentation might be required.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12760859      PMCID: PMC155817          DOI: 10.1128/AAC.47.6.1862-1866.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats.

Authors:  R Roosendaal; I A Bakker-Woudenberg; J C van den Berg; M F Michel
Journal:  J Infect Dis       Date:  1985-08       Impact factor: 5.226

2.  Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal model.

Authors:  J J Mordenti; R Quintiliani; C H Nightingale
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

Review 3.  Role of pharmacokinetics in the outcome of infections.

Authors:  G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

4.  Population pharmacokinetics of continuous infusion ceftazidime.

Authors:  B C Frame; B F Facca; D P Nicolau; S N Triesenberg
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

5.  Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers.

Authors:  J W Mouton; A M Horrevorts; P G Mulder; E P Prens; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

Review 6.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

7.  Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats.

Authors:  C Thauvin; G M Eliopoulos; S Willey; C Wennersten; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

8.  The renal clearance of cefuroxime and ceftazidime and the effect of probenecid on their tubular excretion.

Authors:  C A Verhagen; H Mattie; E Van Strijen
Journal:  Br J Clin Pharmacol       Date:  1994-02       Impact factor: 4.335

9.  Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats.

Authors:  R Roosendaal; I A Bakker-Woudenberg; M van den Berghe-van Raffe; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

10.  Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics.

Authors:  A U Gerber; H P Brugger; C Feller; T Stritzko; B Stalder
Journal:  J Infect Dis       Date:  1986-01       Impact factor: 5.226

View more
  4 in total

1.  Assessment of renal function in clinical practice at the bedside of burn patients.

Authors:  J M Conil; B Georges; O Fourcade; T Seguin; M Lavit; K Samii; G Houin; I Tack; S Saivin
Journal:  Br J Clin Pharmacol       Date:  2006-12-07       Impact factor: 4.335

Review 2.  Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters.

Authors:  Sofia K Kasiakou; Kenneth R Lawrence; Nicolaos Choulis; Matthew E Falagas
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  An Overview of the Protein Binding of Cephalosporins in Human Body Fluids: A Systematic Review.

Authors:  C Jongmans; A E Muller; P Van Den Broek; B De Melo Cruz De Almeida; C Van Den Berg; J Van Oldenrijk; P K Bos; B C P Koch
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

4.  Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis.

Authors:  J Riethmueller; S Junge; T W Schroeter; K Kuemmerer; P Franke; M Ballmann; A Claass; S Broemme; R Jeschke; A Hebestreit; D Staab; K Koetz; G Doering; M Stern
Journal:  Infection       Date:  2009-09-05       Impact factor: 3.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.